Table 1 Baseline characteristic of patients
Age-yr | |
|---|---|
Median | 60 |
Range | 21–81 |
Sex-no. (%) | |
Male | 39 (56,5) |
Female | 30 (43,5) |
ECOG performance status- no.(%) | |
0 | 20 (29) |
1 | 37 (53) |
2 | 12 (18) |
Site of primitive melanoma- no.(%) | |
skin | 58 (84) |
uveal | 3 (4) |
mucosal | 2 (3) |
unknown | 6 (9) |
Melanoma stage-no.(%) | |
M1a | 5 (8) |
M1b | 13 (18) |
M1c | 51 (74) |
Site of metastases-no.(%) | |
1 | 16 (25) |
2 | 19 (27) |
≥ 3 | 34 (48) |
Brain metastases-no.(%) | |
yes | 10 (15) |
no | 59 (85) |
BRAF status-no. (%) | |
Wild type | 31 (46) |
BRAF V600 | 7 (13) |
BRAF not V600 | 3 (2) |
Unknown | 28 (41) |
Prior adjuvant therapy no.(%) | |
vaccine | 2 (3) |
interferon | 13 (19) |
none | 54 (47) |
Disease free survival-months | |
Median | 13 |
Range | 0–136 |
Basal level of LDH (normal range 240–480 mg/dl) | |
High | 29 (42) |
Normal | 40 (58) |